| Academic Achievements |
■ Selected Publications
|
1. |
2019 |
Article |
A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Global Health & Medicine 1,pp.36--48 (Collaboration) |
|
2. |
2019 |
Article |
Novel protease inhibitors containing C-5-modified bis-THF and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with high genetic barrier against the emergence of drug resistance. Antimicrobial Agents and Chemotherapy 25(63(8)),pp.e00372--19 (Collaboration) |
|
3. |
2018 |
Article |
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. 6(9(2)),pp.e02425--17 (Collaboration) |
|
4. |
2017 |
Article |
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. eLife 17(6),pp.e28020 (Collaboration) |
|
5. |
2015 |
Article |
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Jornal of Virology 18(90(5)),pp.01829--15 (Collaboration) |
|
